{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:44:27Z","timestamp":1789731867886,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51909-w","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:32:54Z","timestamp":1784590374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Protein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors"],"prefix":"10.1038","volume":"16","author":[{"given":"Yunsa","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"51909_CR1","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.ccell.2024.06.004","volume":"42","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Multi-scale signaling and tumor evolution in high-grade gliomas. Cancer Cell. 42, 1217\u201338e19 (2024).","journal-title":"Cancer Cell."},{"key":"51909_CR2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ccell.2024.06.002","volume":"42","author":"YJ Wang","year":"2024","unstructured":"Wang, Y. J. et al. Advancing presurgical non-invasive molecular subgroup prediction in medulloblastoma using artificial intelligence and MRI signatures. Cancer Cell 42, 1239\u201357.e7 (2024).","journal-title":"Cancer Cell"},{"key":"51909_CR3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0012","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. CHD2 regulates neuron-glioma interactions in pediatric glioma. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0012 (2024).","journal-title":"Cancer Discov."},{"key":"51909_CR4","doi-asserted-by":"publisher","first-page":"120784","DOI":"10.1016\/j.biomaterials.2021.120784","volume":"273","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy. Biomaterials 273, 120784 (2021).","journal-title":"Biomaterials"},{"key":"51909_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202300570","volume":"19","author":"R Xie","year":"2023","unstructured":"Xie, R. et al. Hsp70-targeting and size-tunable nanoparticles combine with PD-1 checkpoint blockade to treat glioma. Small 19, e2300570 (2023).","journal-title":"Small"},{"key":"51909_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202304187","volume":"35","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Fruit-derived extracellular-vesicle-engineered structural droplet drugs for enhanced glioblastoma chemotherapy. Adv. Mater. 35, e2304187 (2023).","journal-title":"Adv. Mater."},{"key":"51909_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1152\/physrev.00050.2017","volume":"99","author":"MD Sweeney","year":"2019","unstructured":"Sweeney, M. D. et al. Blood-Brain Barrier: From Physiology to Disease and Back. Physiol. Rev. 99, 21\u201378 (2019).","journal-title":"Physiol. Rev."},{"key":"51909_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326\u201341 (2017).","journal-title":"Cancer Cell"},{"key":"51909_CR9","doi-asserted-by":"publisher","first-page":"8318","DOI":"10.1021\/acs.nanolett.9b03968","volume":"19","author":"S Ruan","year":"2019","unstructured":"Ruan, S. et al. Aggregable Nanoparticles-Enabled Chemotherapy and Autophagy Inhibition Combined with Anti-PD-L1 Antibody for Improved Glioma Treatment. Nano Lett. 19, 8318\u20138332 (2019).","journal-title":"Nano Lett."},{"key":"51909_CR10","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ccell.2024.05.001","volume":"42","author":"J Zhong","year":"2024","unstructured":"Zhong, J. et al. Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. Cancer Cell 42, 968\u201384.e9 (2024).","journal-title":"Cancer Cell"},{"issue":"1","key":"51909_CR11","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41467-023-37328-9","volume":"14","author":"P Zhang","year":"2023","unstructured":"Zhang, P. et al. STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nat. Commun. 14(1), 1610 (2023).","journal-title":"Nat. Commun."},{"key":"51909_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.ccell.2022.08.014","volume":"40","author":"A Chryplewicz","year":"2022","unstructured":"Chryplewicz, A. et al. Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. Cancer Cell 40, 1111\u201327.e9 (2022).","journal-title":"Cancer Cell"},{"key":"51909_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","volume":"32","author":"D Saha","year":"2017","unstructured":"Saha, D., Martuza, R. L. & Rabkin, S. D. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell 32, 253\u201367.e5 (2017).","journal-title":"Cancer Cell"},{"key":"51909_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","volume":"130","author":"EN Hoogenboezem","year":"2018","unstructured":"Hoogenboezem, E. N. & Duvall, C. L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliv. Rev. 130, 73\u201389 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"51909_CR15","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1039\/C5CS00158G","volume":"45","author":"Z Liu","year":"2016","unstructured":"Liu, Z. & Chen, X. Simple bioconjugate chemistry serves great clinical advances: Albumin as a versatile platform for diagnosis and precision therapy. Chem. Soc. Rev. 45, 1432\u20131456 (2016).","journal-title":"Chem. Soc. Rev."},{"key":"51909_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102379","volume":"99","author":"D Shastri","year":"2024","unstructured":"Shastri, D., Raj, V. & Lee, S. Revolutionizing Alzheimer\u2019s treatment: Harnessing human serum albumin for targeted drug delivery and therapy advancements. Ageing Res. Rev. 99, 102379 (2024).","journal-title":"Ageing Res. Rev."},{"key":"51909_CR17","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.2174\/138161282114150326101436","volume":"21","author":"F Yang","year":"2015","unstructured":"Yang, F. & Liang, H. Editorial: HSA-based drug development and drug delivery systems. Curr. Pharm. Des. 21, 1784 (2015).","journal-title":"Curr. Pharm. Des."},{"key":"51909_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ijbiomac.2021.10.040","volume":"193","author":"R Solanki","year":"2021","unstructured":"Solanki, R. et al. Anticancer nano-delivery systems based on bovine serum albumin nanoparticles: A critical review. Int. J. Biol. Macromol. 193, 528\u2013540 (2021).","journal-title":"Int. J. Biol. Macromol."},{"key":"51909_CR19","doi-asserted-by":"publisher","first-page":"7422","DOI":"10.1007\/s12274-023-5474-8","volume":"16","author":"W Ban","year":"2023","unstructured":"Ban, W. et al. A boronic acid conjugation integrates antitumor drugs into albumin-binding prodrugs-based nanoparticles with robust efficiency for cancer therapy. Nano Res. 16, 7422\u201330 (2023).","journal-title":"Nano Res."},{"key":"51909_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai, N. et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12, 1317\u201324 (2006).","journal-title":"Clin. Cancer Res."},{"key":"51909_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.addr.2017.02.003","volume":"122","author":"AM Sofias","year":"2017","unstructured":"Sofias, A. M. et al. The battle of \u201cnano\u201d paclitaxel. Adv. Drug Deliv. Rev. 122, 20\u201330 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"51909_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley, D. A. Nab-Paclitaxel mechanisms of action and delivery. J. Control. Release 170, 365\u201372 (2013).","journal-title":"J. Control. Release"},{"key":"51909_CR23","first-page":"2831","volume":"31","author":"Y Yang","year":"2018","unstructured":"Yang, Y., Lu, Z. S. & Zeng, Z. Clinical efficacy and safety of combination of Abraxane and trastuzumab in treatment of recurrent ovarian cancer. Pak. J. Pharm. Sci. 31, 2831\u20132834 (2018).","journal-title":"Pak. J. Pharm. Sci."},{"key":"51909_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121140","volume":"278","author":"D Hwang","year":"2021","unstructured":"Hwang, D. et al. Bioequivalence assessment of high-capacity polymeric micelle nanoformulation of paclitaxel and Abraxane in rodent and non-human primate models using a stable isotope tracer assay. Biomaterials 278, 121140 (2021).","journal-title":"Biomaterials"},{"key":"51909_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2967\/jnumed.110.080606","volume":"52","author":"X Sun","year":"2011","unstructured":"Sun, X. et al. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J. Nucl. Med. 52, 140\u20136 (2011).","journal-title":"J. Nucl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51909-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51909-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51909-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:32:55Z","timestamp":1784590375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51909-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51909"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51909-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"23 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22779"}}